RxDoctor Payments Data

Yohan Han Hwang

Family · Lemon Grove, CANPI 1609515642

Payments from drug & device makers

$1,236in general payments, 2019–2025

Across 28 payments — averaging $44.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • Xeris Pharmaceuticals, Inc.$170
  • E.r. Squibb & Sons, L.L.C.$146
  • Boston Scientific$136
  • Johnson & Johnson$134
  • Lilly USA, LLC$98
  • plus $261 from 10 others

What the payments were for

  • Food & beverage$1,236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,236 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$380,197
Medicare patients
337
Services billed
6,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium39$44,932
XareltoRivaroxaban31$18,605
VascepaIcosapent Ethyl16$5,073
Lidocaine27$2,172
Albuterol Sulfate HfaAlbuterol Sulfate74$1,869
Gabapentin22$615
Ezetimibe41$437
Omeprazole18$420
Amoxicillin38$415
Atorvastatin Calcium66$391
Paxlovid (Eua)Nirmatrelvir/Ritonavir20$340
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$278
Omega-3 Acid Ethyl Esters16$251
Levothyroxine Sodium49$232
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$134$18,60531 claims
Lilly USA, LLCOlanzapine$98$11512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Lemon Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →